148 related articles for article (PubMed ID: 16884970)
1. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
Furst DE; Wallis R; Broder M; Beenhouwer DO
Semin Arthritis Rheum; 2006 Dec; 36(3):159-67. PubMed ID: 16884970
[TBL] [Abstract][Full Text] [Related]
2. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
Ehlers S
Clin Infect Dis; 2005 Aug; 41 Suppl 3():S199-203. PubMed ID: 15983900
[TBL] [Abstract][Full Text] [Related]
4. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
[TBL] [Abstract][Full Text] [Related]
5. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.
Wallis RS; Ehlers S
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):34-8. PubMed ID: 15852254
[TBL] [Abstract][Full Text] [Related]
7. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of latent granulomatous infections by infliximab.
Wallis RS; Broder M; Wong J; Lee A; Hoq L
Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
[TBL] [Abstract][Full Text] [Related]
9. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
Strangfeld A; Listing J
Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
[TBL] [Abstract][Full Text] [Related]
10. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
12. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
13. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.
Liao H; Zhong Z; Liu Z; Zou X
Int J Rheum Dis; 2017 Feb; 20(2):161-168. PubMed ID: 28160418
[TBL] [Abstract][Full Text] [Related]
15. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
Wallis RS
Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
[TBL] [Abstract][Full Text] [Related]
17. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.
Simonini G; Druce K; Cimaz R; Macfarlane GJ; Jones GT
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1073-84. PubMed ID: 24740981
[TBL] [Abstract][Full Text] [Related]
18. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis.
Maccora I; Fusco E; Marrani E; Ramanan AV; Simonini G
Rheumatology (Oxford); 2021 Feb; 60(2):568-587. PubMed ID: 33219694
[TBL] [Abstract][Full Text] [Related]
19. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
20. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.
Arstikyte I; Kapleryte G; Butrimiene I; Venalis A
Biomed Res Int; 2015; 2015():604872. PubMed ID: 26064930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
